Drug pricing isn’t a mystery—it’s a spreadsheet.
If you’ve ever wondered why two drugs with similar therapeutic value can carry wildly different price tags, the answer often isn’t “market forces.” It’s structure: how pricing is calculated, who gets t…

Mark Cuban’s generic-drug play isn’t just another healthcare headline—it’s a stress test for the entire drug pricing ecosystem.
For years, the industry’s default narrative has been simple: innovation is expensive, patents protect investment, and generi…

Biotech hiring isn’t just about headcount. It’s often about patent strategy—and the job postings can be the earliest signal that a company is preparing for a licensing deal, a product launch, or a legal fight.
Here’s the agitation: most people read bio…

Pharma’s “Patent Cliff” Isn’t a Cliff. It’s a Business Model.
The industry tells a familiar story: patents expire, revenues fall, and companies scramble to replace lost exclusivity. But if you look closely at how reformulated drugs are used in practice…

Drug pricing transparency is having a moment. In boardrooms and policy circles, it’s become a default “fix”: publish more data, shine a brighter light, and—somehow—prices will behave.
But what if the cure is worse than the disease?
The argument in the …

Mark Cuban’s “cost-plus” pitch is more than a consumer-friendly pricing story—it’s a strategic stress test for Big Pharma’s entire operating model.
Here’s the agitation: if you’re in healthcare, investing, policy, or even procurement, you can’t treat t…

Pharma doesn’t “discover” patent strategy—it operates it.
Behind every headline about a new drug launch or a blockbuster’s longevity is a quieter, more technical race: tracking IND and NDA timelines with enough precision to win global patent extensions…

Pharma doesn’t “miss” patent dates. It just doesn’t miss them publicly.
Behind the scenes, companies build meticulous timelines to track IND and NDA milestones—because those dates can quietly determine whether a drug gets meaningful patent life extensi…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …

Generic drug approvals aren’t won in the lab—they’re won in the data.
If you’ve ever watched a complex generic stall at the finish line, you already know the frustrating truth: the science is only half the battle. The other half is bioequivalence str…